Navigation Links
MMJ BioScience Moving Forward with Cannabis Multiple Sclerosis FDA Study
Date:8/27/2017

MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it's affiliate MMJ Bioscience has engaged Bianca Weinstock-Guttman, MD, as their principal investigator.

Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York at Buffalo and serves as Executive Director of the New York State Multiple Sclerosis Consortium. She will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ BioScience's will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ BioScience’s first pharmaceutical cannabidiol (CBD) derived medicine.

A large percentage of Multiple Sclerosis patients are resistant to currently available treatments and experience symptoms including spasticity and pain. These conditions are difficult to manage and treatment options are currently limited. The day-to-day impact of these devastating conditions are significant and with high rates of mortality, there is a considerable unmet patient need for MMJ BioScience’s novel new drug.

Tom Ryan, MMJ’s COO stated that, “MMJ BioScience’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, contract processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.”

"Our initiation of the Phase 2 clinical trial programs and the eventual FDA Fast Track Designation for Progressive Multiple Sclerosis signify important steps forward in MMJ BioScience's ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients," stated Tom Ryan.

According to the FDA, Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need In the U.S. The FDA Orphan Drug Designation is granted to medicines and biologics that are defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S.

While a growing number of states have legalized marijuana for medical use, medical marijuana differs from pharmaceutical treatments in that even state to state legal forms are not FDA regulated. For this reason, there is no way to ensure consistency between batches or even that there is accurate product labeling.

In addition, there is no standardization in terms of how these products are prescribed or dosed for specific conditions. The MMJ BioScience team will be carefully conducting these controlled studies to determine the benefits and risks of medical marijuana products for safe patient use.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14637320.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. CNA Finance Provides Research Update On Aytu Bioscience And Natesto®
2. Tosoh Bioscience LLC Announces Partnership with PolyAnalytik Inc.
3. CNA Finance Initiates Research Coverage On Aytu Bioscience
4. Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
5. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
6. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
7. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
8. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
9. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
10. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
11. Roka Bioscience to participate in the 40th Annual National Food Policy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):